Introduction: It is not uncommon for a woman to suffer from abnormal uterine bleeding (AUB) or heavy menstrual bleeding (HMB) at some point during her lifetime. Once pathology is excluded, in practice, management needs to be individualised, taking into account the improvement of the woman's symptoms and quality of life.
Introduction
'There can be no other disease or condition that affects so many people on such a regular basis with consequences, at both the individual and societal levels, which is not prioritised in some way by health professionals or policy makers'. 1 Abnormal uterine bleeding (AUB) describes a range of symptoms, such as heavy menstrual bleeding (HMB, bleeding above the 95th centile of the normal population), inter-menstrual bleeding and a combination of both heavy and prolonged menstrual bleeding. This terminology was established by the International Federation of Gynecology and Obstetrics (FIGO) Menstrual Disorders Working Group in 2011 and has been gaining global acceptance. The diagnosis of AUB can be made when conditions within the acronym PALM-COEIN are implicated ( Fig. 1 )-PALM (polyps, adenomyosis, leiomyoma, malignancy) and COEIN (coagulopathies, ovulatory dysfunction, endometrial, iatrogenic, not otherwise classified). 2 Menstrual disorders, previously portrayed as dysfunctional uterine bleeding (DUB) and menorrhagia, are now better described as abnormal uterine bleeding (AUB). 3 The terms DUB and menorrhagia should be discarded. 4 In clinical practice, HMB is defined as 'excessive menstrual blood loss leading to interference with the physical, emotional, social and material quality of life of a woman'. 5 Hence, treatment success ultimately depends on the improvement of the woman's symptoms and quality of life.
The volume of menstrual flow is influenced in part by uterine contractions, vascular tone and haemostatic function. Normal menstruation can range from a frequency of between 24 and 38 days, a duration between 4.5 and 8 days, and a volume of blood loss between 5 and 80 ml per cycle. 6 The experience of menstruation is different for every woman. Therefore, defining what constitutes 'abnormal' menstrual bleeding is a subjective assessment for patients and their clinicians. The definition of HMB in the research setting relates to blood loss of more than 80 ml per cycle. 7 This level of blood loss increases the risk of iron deficiency anaemia. 8 Despite its relative frequency, AUB continues to be a significant and at times unmet clinical need. Standardising assessment tools for measuring outcomes of AUB is the focus of current work being developed through the Crown Initiative (Core Outcomes in Women's and Newborn Health), aiming to address the widespread, unwarranted variation in reporting of women's health outcomes. Abnormal uterine bleeding across the life course AUB may first manifest at the onset of the menarche. 10 It is particularly prevalent in women of reproductive age, but continues to be a common problem until menopause. As such, the clinico-pathological spectrum of uterine diseases that may be involved, and the management strategy adopted, depends very much on the risk profile of individual at the time of presentation. Menstrual problems are common in adolescence with many suffering from unpredictable, prolonged or heavy bleeding soon after menarche. Adolescents frequently have irregular and/or painful periods, but occasionally experience unpredictable, prolonged or excessive bleeding that may present as a medical emergency. 11 Anovulation is likely to be the most common reason for HMB in this age group 12 but other causes, such as an underlying bleeding disorder, are essential to exclude. In the reproductive years, AUB and its subgroup HMB affects~14-25% of women and impacts significantly on physical, social, emotional and psychological aspects of the quality of life. 13 Two national audits in England and Wales 14, 15 reported that, at 1 year post referral, only a third of women (including those who underwent surgery) were 'satisfied' (or better) at the prospect of current menstrual symptoms continuing for the next 5 years. A postal survey of 4610 women (aged 25-44 years) in Scotland found that 30-35% of women reported 'menorrhagia', and one-fifth of these women felt that their periods were a problem. Reporting period problems was directly proportional to the incidence of dysmenorrhoea and heaviness of the flow. 16 The management of AUB in this group of women, many of whom wish to retain fertility, often poses a challenge, as current effective treatments for AUB often render the patient infertile. Specific considerations therefore have to be made in this group to balance the woman's desire for fertility against the need for symptomatic treatment of AUB. During the premenopausal phase, the menstrual cycles are shortened, often anovulatory and irregular. The irregular pattern of bleeding may be exacerbated by 'Luteal Out of Phase Events' (LOOP), where the mid-cycle oestradiol peak is followed by a second or even third peak that is yet higher. The last oestradiol peak and subsequent rise of progesterone after flow starts in the following cycle, determines the presence of menstrual symptoms. Hale estimated that a third of cycles during the menopausal transition have LOOP characteristics. 17 The increased frequency of anovulatory cycles, and consequent exposure of the endometrium to unopposed oestrogen, increases the risk of endometrial hyperplasia and endometrial carcinoma in peri-menopausal and post-menopausal women with AUB.
While the management of AUB should be diseasespecific and address underlying pathology, individualising treatment strategies and management of patient expectations are crucial for a successful outcome. In the sections below, we examine the clinical approach to patients with AUB and review the evidence-based medical and surgical treatment options.
The clinical approach to abnormal uterine bleeding
The first step in the diagnostic workup is to assess the 'quantity' of menstrual blood loss and the impact on the patient. Various charts, questionnaires and diseasespecific patient-reported outcome measures (PROMs) are available. However, these are not commonly used in the clinic as there is limited evidence that they alter patient outcomes. Whilst research is being conducted to develop clinically useful validated PROMs and bleeding scores, 18, 19 in practice, the clinician must rely on individual assessment to investigate AUB. The clinical approach to assessing a patient with AUB can be taken in several steps. bleeding such as hypothyroidism, hyperprolactinaemia, polycystic ovary syndrome, adrenal or hypothalamic disorders (e) Coagulation disorders: History of (i) excessive menstrual bleeding since menarche, or (ii) one of the following-postpartum haemorrhage, surgery-related bleeding, or bleeding associated with dental work, or (iii) two or more of the following-bruising greater than 5 cm once or twice a month, epistaxis once or twice a month, frequent gum bleeding, family history of bleeding symptoms. 21 The presence of a significant clinical history, together with abnormalities in investigation results ( Table 2 shows a list of investigations that may be useful in the context of AUB.
General management strategies
In practice, if there is an obvious pathology identified, the key management strategy will be aimed at treating the cause through medical or surgical treatment (Fig. 2) . Women with severe symptoms (those with severe pain or pressure symptoms) may require treatment that results in a swifter resolution and clinicians may lean towards a surgical approach if an effective strategy is available. Table 3 14 lists the recommended treatments for AUB with and without identifiable treatable pathology. For more detailed reviews on the individual topics, refer to the following references. [23] [24] [25] Where no obvious pathology has been identified, the abnormal bleeding is likely to be attributed to local endometrial causes. However, currently, there are no ideal diagnostic or monitoring tools Medical treatment is tailored to the individual woman's therapeutic goals. Desire for pregnancy or contraception, underlying medical conditions, and tolerance of side effects will encourage compliance and maximise the likelihood of treatment success.
For medical options, besides the treatment of iron deficiency anaemia (Table 1) , 28 the management of AUB can be divided into non-hormonal and hormonal therapies. Non-hormonal treatments, including anti-fibrinolytics and non-steroidal antiinflammatory drugs (NSAIDs) can reduce menstrual blood loss by up to a 50%. 29, 30 These are appropriate first-line options for women who wish to conceive or avoid hormonal side effects. In addition, they also confer the benefit of a degree of analgesia. Anti-fibrinolytics and NSAIDs may also be used in conjunction. However, they are less likely to be effective in the presence of significant pathology, such as uterine fibroids.
The choice of hormonal treatment very much depends on the patients' preferences. With regard to hormonal treatments, the combined oral contraceptive pill (COCP) is widely used to regulate bleeding and 
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If Age > 40 yrs; or <40 yrs with high risk Hysteroscopy for possible endometrial carcinoma/hyperplasia reduce blood loss, although there are minimal data from randomised trials to demonstrate clinical benefit. Treatment consecutively for 3 months without a pill free week may be of value. 31 Oral progestogens may be used to stop an acute heavy bleed, to manage irregular or heavy bleeding or to control the timing of the onset of menstruation, although side effects may limit longer term use. 32 In women with HMB who presented to primary care providers, the levonorgestrel intrauterine system (LNG-IUS) was reported to be more effective than other first-line medical treatments in reducing the impact of HMB on quality of life. 33 However, insertion of the intrauterine system into the uterus may prove difficult, particularly in the presence of lesions such as large submucous fibroids, or fibroids that alter the structure of the uterine cavity. In addition to providing effective contraception, injectable progestogens (such as depot medroxyprogesterone acetate DMPA) cause amenorrhoea in up to 50% of users, 34 though this approach may also be associated with troublesome breakthrough bleeding. Gonadotrophin releasing hormone agonists (GnRHa) are known to induce amenorrhoea in up to 90% of women. This treatment is often used in women with fibroids, effectively shrinking the size of fibroids and reducing operative blood loss if surgery is subsequently undertaken. [35] [36] [37] However, side effects due to the associated hypo-oestrogenic state may be significant. Use is usually limited to 6 months prior to elective surgery. If longer term treatment is contemplated, 'add-back' hormone replacement therapy may be prescribed to reduce side effects and protect against osteoporosis. Selective progesterone receptor modulators (SPRMs) are a newer group of pharmacological agents possessing tissue-specific progesterone antagonistic effects on the endometrium and myometrium. With good treatment compliance, clinical trials have demonstrated control of HMB in women with fibroids in over 90% of cases and amenorrhoea in over 70%. There is good evidence that the SPRM, ulipristal acetate (UPA), compares well with GnRHa for pre-surgery treatment of uterine fibroids, and is better tolerated.
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Repeated 12-week courses of daily oral ulipristal acetate (5 and 10 mg) have recently been shown to control bleeding and pain, reduce fibroid volume, and restore quality of life in patients with symptomatic fibroids. 39 The investigators concluded that the 5 mg dose of ulipristal acetate approved for pre-operative use would be appropriate for long-term symptom management, although the data available thus far are only based on up to four repeated courses. Administration of all SPRMs is associated with a 'class-effect' on the endometrium known as 'progesterone receptor modulator associated endometrial changes' (PAEC). 40 This unique morphology, encompassing endometrial glandular changes with architectural irregularity, with cystic dilatation and with the glandular epithelium appearing inactive, with no physiological secretary appearance, requires recognition 
Surgical treatment
A detailed discussion about the surgical management of malignancy, fibroids, adenomyosis, uterine anomalies and polyps is beyond the scope of this review but suggested references include the following. 23, [41] [42] [43] [44] Surgical management, in the absence of underlying pathology (i.e. surgical management of HMB) takes the form of either endometrial destruction or hysterectomy. Endometrial destruction is only applicable when the patient's family is complete or she utilises a permanent/highly reliable method of contraception. The endometrium may be removed by surgical resection (first-generation hysteroscopic techniques), or through controlled application of energy (second-generation techniques, e.g. heat, cold, microwave), to produce full thickness necrosis. Risks of endometrial ablation include uterine perforation, infection, haemorrhage, and bowel or bladder injury. Other risks of hysteroscopic techniques are fluid overload, especially with hypotonic solutions (e.g. 1.5% glycine), leading to symptoms of hyponatraemia and post-ablation syndrome, often present as cyclical pain, as a result of haematometra.
A summary of the current RCTs comparing the surgical management of HMB is outlined in Figure 3 . A recent Cochrane systematic review found that success rates and complication profiles of newer techniques of ablation compare favourably with hysteroscopic techniques. 22 In comparison with hysterectomy, endometrial destruction techniques have a shorter operation time and hospital stay, quicker recovery, fewer postoperative complications and similar satisfaction rates. Hence, in practice, most clinicians initially perform endometrial ablation using one of the second-generation techniques unless a polyp or fibroid need to be removed, when a hysteroscopic resection technique will be more appropriate. Ongoing reliable contraception is essential for sexually active women after endometrial ablation/ destruction. Although fertility is usually significantly impaired, conception is possible and is associated with an increased risk of serious complications, including abnormal placentation and major haemorrhage. The review also compared endometrial resection with medical treatments (hormonal and nonProgestogens, the combined oral contracepƟve pill, tranexamic acid, hormone replacement therapy and non-steroidal anƟ-inflammatory drugs Fig. 3 A summary of the current RCTs comparing the surgical management of HMB.
hormonal). Endometrial resection was more effective in controlling bleeding at 4 months (RR 2.66, 95% CI 1.94-3.64, one RCT, 186 women, moderatequality evidence) and at 2 years (RR 1.29, 95% CI 1.06-1.57, one RCT, 173 women, low quality evidence) although no difference was seen at 5 years (RR 1.14, 95% CI 0.97-1.34, one RCT, 140 women). Indeed, the satisfaction with treatment achieved at 2 years was not maintained at 5 years.
Regrettably, there were insufficient data to perform a meaningful head-to-head comparison between specific types of surgery and individual medical treatments.
In the same review, when hysterectomy was compared with the LNG-IUS, the hysterectomy group was more likely to have objective control of bleeding at 1 year (RR 1.11, 95% CI 1.05-1.19, one RCT, 223 women, moderate-quality evidence). There was no difference in quality of life between the groups at 5 or 10 years, but a significant proportion of women (46%) assigned to the LNG-IUS had undergone hysterectomy by 10 years.
Predictably, for most trials, it was not possible to recruit women who had never had any form of medical treatment. Hence, this was a significant confounder in favour of surgery over medical therapies.
Clearly, the decision for conservative or major surgery versus any form of medical treatment is dependent on the patient's fertility aspirations, fitness and preference. Surgery carries complications such as the injury to viscera, bleeding, venous thromboembolism and infection. In some patients, these risks may be not insignificant. Women should ideally try less invasive treatments with the lowest complication rates as first-line therapy.
Conclusion
The management of the patient with AUB requires a step-by-step approach, where treatment is customised to the individual's needs, addressing any underlying pathology and taking into account the desire, or not, for preservation of fertility. There is however, in addition to the introduction of new treatments, a need for the development of novel tools to help diagnose, monitor and quantify the severity of the disorder. But let us not forget that no therapeutic discovery will ever eliminate the need for good judgement, sensitive communication and the art of managing expectations.
